<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02282098</url>
  </required_header>
  <id_info>
    <org_study_id>NIF-14350</org_study_id>
    <secondary_id>NIF-14350</secondary_id>
    <nct_id>NCT02282098</nct_id>
  </id_info>
  <brief_title>Colchicine in Atrial Fibrillation to Prevent Stroke</brief_title>
  <acronym>CIAFS-1</acronym>
  <official_title>Targeting Inflammation in Atrial Fibrillation to Prevent Ischemic Stroke: A Feasibility Study Evaluating the Effect of Colchicine on D-dimer and Hs-CRP in Anticoagulated Patients With Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Population Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Population Health Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the feasibility of performing a randomized
      controlled trial to investigate the efficacy of an anti-inflammatory drug, colchicine, at
      reducing well validated markers of thrombosis (D-dimer) and inflammation (hs-CRP).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Atrial fibrillation (AF), the most common cardiac arrhythmia (with a global burden of 33.5
      million affected patients in 2010), is responsible for about 20% of ischemic stroke, a major
      cause of morbidity and mortality. Anticoagulants are very effective in reducing the risk of
      stroke in AF but on average 10-15% of treated patients still experience a stroke over a
      10-year period and in selected elderly populations the risk is even higher. We hypothesize
      that thrombosis mediated by inflammation might be responsible for the residual risk of
      stroke, despite anticoagulant therapy and that targeting inflammation has the potential to
      reduce thrombosis and the risk of stroke in anticoagulated patients with AF.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recruitment rates</measure>
    <time_frame>Randomization to Month 3</time_frame>
    <description>Number of eligible patients successfully randomized into study per year of study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drop-out rates</measure>
    <time_frame>Randomization to Month 3</time_frame>
    <description>Proportion of participants withdrawing from study for any reason</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>D-dimer</measure>
    <time_frame>Randomization to Month 3</time_frame>
    <description>Mean D-dimer level at baseline and Month 3 for each arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hs-CRP</measure>
    <time_frame>Randomization to Month 3</time_frame>
    <description>Mean level of hs-CRP at baseline and month 3 for each arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with a clinically significant adverse event</measure>
    <time_frame>Randomization to Month 3</time_frame>
    <description>Proportion of patients with side effects such as diarrhoea, myopathy requiring drug cessation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug adherence</measure>
    <time_frame>Randomization to Month 3</time_frame>
    <description>Proportion of missing pill to dispensed pill at 6 weeks and month 3</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Active Colchicine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intervention group will receive colchicine 0.6 mg twice daily orally for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Colchicine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The control group will receive colchicine placebo 0.6mg twice daily orally for 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine</intervention_name>
    <description>Colchicine 0.6mg twice daily</description>
    <arm_group_label>Active Colchicine</arm_group_label>
    <other_name>pms-Colchicine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Colchicine</description>
    <arm_group_label>Placebo Colchicine</arm_group_label>
    <other_name>Placebo Capsule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with atrial fibrillation who has been receiving chronic anticoagulation for
             at least 3 months.

        Exclusion Criteria:

          -  Contraindications to colchicine such as allergy/hypersensitivity,

          -  Receiving colchicine or other anti-inflammatory drugs (such as corticosteroids,
             methotrexate, anti-neoplastic, Interleukin 1-1b antagonist, Tumor necrosis
             factor-alpha inhibitor),

          -  Receiving food or co-medications such as strong-moderate cytochrome P450 3A4
             inhibitors that will result in elevated plasma level of colchicine,

          -  Inflammatory disorders (SLE, Rheumatoid arthritis, connective tissue disorder) or
             chronic infection,

          -  Severe renal (eGFR&lt; 30ml/min/1.73m2), or liver failure or liver aminotransferase
             (ALT/AST &gt; 2x Upper limit of normal),

          -  Moderate or severe cytopenias (platelet &lt; 100, neutrophil count &lt; 1.5) or existing
             blood dyscrasia (e.g., myelodysplasia)

          -  Pregnant or lactating woman or woman of child bearing age no protected by reliable
             contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Noel Chan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Population Health Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Eikelboom, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Population Health Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Debi Sloane</last_name>
    <phone>905-527-4322</phone>
    <phone_ext>40408</phone_ext>
    <email>debi.sloane@phri.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexandra Sabev</last_name>
    <phone>905-527-4322</phone>
    <phone_ext>40663</phone_ext>
    <email>Alexandra.Sabev@phri.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hamilton General Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandra Sabev, CCRA</last_name>
      <phone>905-527-4322</phone>
      <phone_ext>40663</phone_ext>
      <email>alexandra.sabev@phri.ca</email>
    </contact>
    <investigator>
      <last_name>John Eikelboom, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2014</study_first_submitted>
  <study_first_submitted_qc>October 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2014</study_first_posted>
  <last_update_submitted>October 28, 2016</last_update_submitted>
  <last_update_submitted_qc>October 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Population Health Research Institute</investigator_affiliation>
    <investigator_full_name>Noel Chan</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>Atrial fibrillation</keyword>
  <keyword>Arrhythmias, Cardiac</keyword>
  <keyword>Stroke</keyword>
  <keyword>agents, anti inflammatory</keyword>
  <keyword>D-dimer</keyword>
  <keyword>C-reactive protein</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

